Pasar al contenido principal

MOLECULAS PARA EL TRATAMIENTO DE ENFERMEDADES COMPLEJAS ASOCIADAS A LA EDAD

SAF2015-65586-R

•
Nombre agencia financiadora Ministerio de Economía y Competitividad
Acrónimo agencia financiadora MINECO
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos I+D+i Retos de Investigación
Año convocatoria 2015
Plan Estatal 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Unidad de gestión Dirección General de Investigación Científica y Técnica
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)
Identificador persistente http://dx.doi.org/10.13039/501100003329

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Recent Advances on Nitrones Design for Stroke Treatment

  • Marco-Contelles, José
The recent advances of tetramethylpyrazine nitrones and quinolylnitrones for the treatment of stroke have been reviewed and compared with other agents, showing promising therapeutic applications. As a result of a functional transformation of natural product ligustrazine, (Z)-N-tert-butyl-1-(3,5,6-trimethylpyrazin-2-yl)methanimine oxide (6) is a multitarget small nitrone showing potent thrombolytic activity and free radicals scavenging power, in addition to nontoxicity and blood-brain barrier permeability. Similarly, antioxidant (Z)-N-tert-butyl-1-(2-chloro-6-methoxyquinolin-3-yl)methanimine oxide (17) is a novel agent for cerebral ischemia therapy as it is able to scavenge different types of free radical species, showing strong neuroprotection and reduced infarct size., J.M.-C. thanks MINECO (Government of Spain, GrantSAF2015-65586-R), UCJC (Grants UCJC 2020-03 and UCJC2020-33), and ISCIII (Grant RD06/0026/1002) for support.J.M.-C. thanks Dr. Alcàzar (Department of Investigation,IRYCIS, Hospital Ramón y Cajal, Madrid, Spain), Prof. Oset-Gasque (Department of Biochemistry and Molecular Biology II,School of Pharmacy, UCM, Madrid, Spain), and Prof.Piotrowska (Faculty of Pharmacy, Medical University of Lodz,Poland) for continued collaboration. J.M.-C. also thanks theRENEVAS staff, in particular Pepe Castillo, Nacho Lizasoaìn,Marìa A. Moro, Antonio Dàvalos, and Joan Montaner, forstimulating and fruitful discussions. Figures 5−7 and Table 1 area reproduction of Figures 4, 7, 11, and Table 1, respectively, fromref66; Figures 9 and 10 are a reproduction of Figures 1 and 2,respectively, from ref65; Figure 12 is a reproduction of Figure 5from ref77, and for these reasons I thank the authors